Spring has sprung and so has March’s edition of The Radiology Rundown. It’s been a month filled with lots of new updates, along with plenty more conferences and events in the world of radiology and the wider medical imaging space.
FDA / Market Approvals
Subtle Medical announced CE mark for their SubtleHD product. Expect to see them making a big impact in Europe this year.
Intrasense also achieved CE mark for their AI solution for the detection of bone lesions on CT scan images, co-developed with Guerbet.
Gleamer also had a successful month for market approvals, with Chestview achieving FDA clearance for CADe.
Funding
UK based Brainomix announced they had secured £14m Series C investment in the stroke AI space. This investment help accelerate their commercial expansion into the USA.
Radiobotics were awarded just shy of £500,000 from SBRI Healthcare, as part of their Competition 26 (Urgent & Emergency Care) funding competition.
In the world of Digital Pathology AI, Proscia secured a huge $50m funding, taking their total raised to $130m. A great talking point for their team heading into USCAP – United States and Canadian Academy of Pathology no doubt.
Partnerships
NVIDIA were at the heart of several partnerships in medical imaging this month. Announcing partnerships with GE HealthCare, Subtle Medical & Hyperfine | AI-Powered Portable MRI.
Expect to see NVIDIA and medical imaging become an ever more common link heading into 2026.
Other key partnerships and collaborations announced this week:
Riverain Technologies X CARPL – Radiology AI Platform
